Obesity Surgery

, Volume 24, Issue 11, pp 1881–1887 | Cite as

Impact of Different Criteria on Type 2 Diabetes Remission Rate After Bariatric Surgery

  • A. Mas-Lorenzo
  • D. Benaiges
  • J. A. Flores-Le-Roux
  • J. Pedro-Botet
  • J. M. Ramon
  • A. Parri
  • M. Villatoro
  • J. Chillarón
  • M. Pera
  • L. Grande
  • A. Goday
  • On Behalf of the Obemar Group
Original Contributions

Abstract

Background

Laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) achieve similar type 2 diabetes mellitus (T2DM) remission rates. Since a great variability exists in defining T2DM remission, an expert panel proposed partial and complete remission criteria that include the maintenance of fasting plasma glucose (FPG) and glycosylated hemoglobin (A1c) objectives for at least 1 year. The 2-year T2DM remission rate and time needed to reach it after LSG or LRYGB were compared using different remission criteria.

Methods

This was a prospective cohort study of 55 T2DM subjects operated on with LSG (n = 21) or LRYGB (n = 34). Four models for defining remission were used: Buchwald criteria (FPG <100 mg/dl or A1c <6 %), American Diabetes Association (ADA) complete (FPG <100 mg/dl plus A1c <6 % maintained for at least 1 year), ADA partial (FPG <125 mg/dl with A1c <6.5 % maintained for at least 1 year), and ADA complete without time requirement.

Results

Both groups were comparable, except for higher A1c levels in the LSG group. The remission rate ranged from 43.6 % using ADA complete remission to 92.7 % with Buchwald criteria, with no differences between surgical procedures. Differences were found in the time to achieve remission only when ADA complete remission criteria (5.1 ± 2.9 months LRYGB and 9.0 ± 3.8 months LSG, p = 0.014) and ADA without time requirement criteria (4.9 ± 2.7 months LRYGB and 8.4 ± 3.9 months LSG, p = 0.005) were used.

Conclusions

T2DM remission rate varies widely depending on the criteria used for its definition. Remission occurred sooner after LRYGB when the strictest criteria to define remission were used.

Keywords

Severe obesity Laparoscopic sleeve gastrectomy Laparoscopic Roux-en-Y gastric bypass Type 2 diabetes mellitus remission 

References

  1. 1.
    Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res ClinPract. 2011;94(3):311–21.CrossRefGoogle Scholar
  2. 2.
    Dixon JB, le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet. 2012;379(9833):2300–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.PubMedCrossRefGoogle Scholar
  4. 4.
    Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.PubMedCrossRefGoogle Scholar
  6. 6.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2012;35 Suppl 1:S11–63.Google Scholar
  7. 7.
    Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36.PubMedCrossRefGoogle Scholar
  8. 8.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMedCrossRefGoogle Scholar
  9. 9.
    Abbatini F, Rizzello M, Casella G, et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24(5):1005–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Blackstone R, Bunt JC, Cortés MC, et al. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis. 2012;8(5):548–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Pournaras DJ, Aasheim ET, Søvik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012;99(1):100–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramos-Levi AM, Cabrerizo L, Matía P, et al. Which criteria should be used to define type 2 diabetes remission after bariatric surgery? BMC Surg. 2013;13:8.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Hubbard VS, Hall WH. National Institutes of Health Consensus Development Conference draft statement on gastrointestinal surgery for severe obesity. Obes Surg. 1991;1(3):257–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Ramos-Levi AM, Sanchez-Pernaute A, Cabrerizo L, et al. Remission of type 2 diabetes mellitus should not be foremost goal after bariatric surgery. Obes Surg. 2013;23(12):2020–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.PubMedCrossRefGoogle Scholar
  20. 20.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRefGoogle Scholar
  21. 21.
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665–73.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–11.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Ackermann RT, Cheng YJ, Williamson DF, et al. Identifying adults at high risk for diabetes and cardiovascular disease using hemoglobin A1c National Health and Nutrition Examination Survey 2005–2006. Am J Prev Med. 2011;40(1):11–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279–86.PubMedCrossRefGoogle Scholar
  26. 26.
    Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36(1):20–6.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7(6):691–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Lee WJ, Chong K, Chen JC, et al. Predictors of diabetes remission after bariatric surgery in Asia. Asian J Surg. 2012;35(2):67–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Jiménez A, Casamitjana R, Flores L, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256:1023–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Vidal P, Ramón JM, Goday A, et al. Laparoscopic gastric bypass versus laparoscopic sleeve gastrectomy as a definitive surgical procedure for morbid obesity. Mid-term results. Obes Surg. 2012;23:292–9.CrossRefGoogle Scholar
  31. 31.
    Kehagias I, Karamanakos SN, Argentou M, et al. Randomized clinical trial of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the management of patients with BMI < 50 kg/m2. Obes Surg. 2011;21:1650–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Yang X, Yang G, Wang W, et al. A meta-analysis: to compare the clinical results between gastric bypass and sleeve gastrectomy for the obese patients. Obes Surg. 2013;23:1001–10.PubMedCrossRefGoogle Scholar
  33. 33.
    Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247(3):401–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Ramón JM, Salvans S, Crous X, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16(6):1116–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • A. Mas-Lorenzo
    • 1
  • D. Benaiges
    • 1
    • 2
    • 5
  • J. A. Flores-Le-Roux
    • 1
    • 2
    • 5
  • J. Pedro-Botet
    • 1
    • 2
  • J. M. Ramon
    • 3
  • A. Parri
    • 1
  • M. Villatoro
    • 1
  • J. Chillarón
    • 1
    • 2
    • 5
  • M. Pera
    • 2
    • 3
  • L. Grande
    • 2
    • 3
  • A. Goday
    • 1
    • 2
    • 4
    • 5
  • On Behalf of the Obemar Group
  1. 1.Department of Endocrinology and NutritionHospital del MarBarcelonaSpain
  2. 2.Universitat Autònoma de BarcelonaBarcelonaSpain
  3. 3.Unit of Gastrointestinal SurgeryHospital del MarBarcelonaSpain
  4. 4.CIBEROBNMadridSpain
  5. 5.Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)BarcelonaSpain

Personalised recommendations